The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
about
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersThe evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimismThe in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agentPhospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.NSAIDs and Colorectal Cancer Control: Promise and ChallengesDevelopment of oseltamivir phosphonate congeners as anti-influenza agentsTopical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22)Aerosol administration of phospho-sulindac inhibits lung tumorigenesisCurcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidateRecent developments in chimeric NSAIDs as safer anti-inflammatory agents.
P2860
Q26739665-3F121552-8234-488E-A2D9-3AB0D3758B1CQ28087427-EEC99681-3D0F-458F-962E-633A2AC278C7Q34079767-F0B449E4-834E-462F-A3CE-1E83036B37BAQ35243621-6DB14C53-9812-42F1-B19A-2D933BADAFA3Q35388614-27338C8F-C881-4B62-90F1-2F4D1F46FA77Q35688543-0450F537-1A9A-4DAB-BF82-6BB62E88E9F0Q36252867-E45C5F6E-593B-4FC2-B3FD-BC279B884C82Q36381490-E03C9B93-558B-4C9D-91D7-E69E87A86AD3Q36382214-CEADEB49-D2A3-4187-AA4C-8205818B44CDQ36642853-E234940B-29E7-4064-9F36-37ABAE9B7B0CQ36645178-680C6329-315F-4BFB-AC77-EFB6B2A02EBCQ36700587-266633A4-8666-483C-B075-1E1B8DA22287Q37191096-E269CE54-769A-483B-B6C7-E4376B2C81FFQ37209494-DFBEC8F7-128B-421D-8CAA-4E48000B054FQ37504288-DA00D78C-8863-4DEB-AE68-19716BF407F7Q38260626-D516EAD3-AF09-4B75-B81A-17C71C0ACF22
P2860
The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The metabolism and pharmacokin ...... ct of difluoromethylornithine.
@ast
The metabolism and pharmacokin ...... ct of difluoromethylornithine.
@en
type
label
The metabolism and pharmacokin ...... ct of difluoromethylornithine.
@ast
The metabolism and pharmacokin ...... ct of difluoromethylornithine.
@en
prefLabel
The metabolism and pharmacokin ...... ct of difluoromethylornithine.
@ast
The metabolism and pharmacokin ...... ct of difluoromethylornithine.
@en
P2093
P2860
P1476
The metabolism and pharmacokin ...... ct of difluoromethylornithine.
@en
P2093
G G Mackenzie
L Kopelovich
O T Murray
P P Constantinides
P2860
P304
P356
10.1111/J.1476-5381.2011.01705.X
P407
P577
2012-04-01T00:00:00Z